Login / Signup

PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.

Sarah J KitsonZoe MaskellVanitha N SivalingamJennifer L AllenSaad AliSean BurnsKyle GilmourRahamatulla LatheefRichard J SladePhilip W PembertonJoseph ShawW David RyderHenry C KitchenerEmma J Crosbie
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Short-term treatment with standard diabetic doses of metformin does not reduce tumor proliferation in women with endometrioid endometrial cancer awaiting hysterectomy. This study does not support a biological effect of metformin in endometrial cancer and casts doubt on its potential application in the primary and adjuvant treatment settings.
Keyphrases
  • phase iii
  • endometrial cancer
  • placebo controlled
  • double blind
  • open label
  • phase ii
  • clinical trial
  • study protocol
  • phase ii study
  • early stage
  • type diabetes
  • combination therapy
  • squamous cell carcinoma
  • smoking cessation